Evaluation of propofol target-controlled infusion (TCI) anaesthesia in infants aged 6 months to 3 years

Submission date	Recruitment status	[X] Prospectively registered
16/08/2008	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
29/08/2008	Completed	Results
Last Edited	Condition category	Individual participant data
21/11/2012	Surgery	[] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Neil Morton

Contact details

Department of Anaesthesia Royal Hospital for Sick Children Glasgow United Kingdom G3 8SJ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 2008/PAEDAN/01

Study information

Scientific Title

Study objectives

The "Paedfusor" model performs within recognised acceptable limits of accuracy when used in children in the age group of 6 months to 3 years.

Ethics approval required

Old ethics approval format

Ethics approval(s)

To be submitted to West Ethics Committee (Glasgow) in September 2008.

Study design

Interventional, single-arm, single-centre trial

Primary study design

Interventional

Secondary study design

Single-centre

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Intravenous general anaesthesia in infants and young children

Interventions

Propofol 2% infusion anaesthesia delivered by TCI system using the "Paedfusor" software.

Details of Joint Sponsor:
NHS Greater Glasgow and Clyde
Dalian House
PO Box 15329
350 St. Vincent Street
Glasgow, G3 8YZ
United Kingdom
http://www.nhsgg.org.uk

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Propofol

Primary outcome measure

Performance of the "Paedfusor" pharmacokinetic model for children aged 6 months - 3 years, weight 7-16 kg as calculated from 4 standard parameters (see below). The performance error (PE) is calculated from the concentration of propofol measured in whole blood (Cmeas) and the concentration predicted by the software (Cpred) as follows:

PE(%) = [(Cmeas Cpred)/Cpred] x 100

The four standard measures of performance are derived from this value, namely bias, precision, divergence and wobble. These derived parameters estimate whether the system over- or underdelivers propofol, by how much and how this varies between patients and for an individual patient over time. The blood propofol samples will be taken throughout surgery and one sample 4 hours afterwards.

Secondary outcome measures

Population pharmacokinetics of propofol in children aged 6 months - 3 years, calculated using non-linear effects modelling (NONMEM). This allows calculations of volume of distribution and clearance of propofol, and any relationships between these pharmacokinetic parameter values and patients age, gender and weight to be statistically evaluated.

Overall study start date

01/11/2008

Completion date

31/12/2009

Eligibility

Key inclusion criteria

- 1. Healthy male and female children aged 6 months 3 years (inclusive)
- 2. Weight 7-16 kg
- 3. Elective surgery of expected duration >=30 minutes
- 4. American Society of Anaesthesiologists (ASA) Grade 1 or 2
- 5. Written informed consent from parent
- 6. Child suitable for intravenous induction and maintenance of anaesthesia with propofol
- 7. Children with no contraindication to application of local anaesthetic cream or gel to the cannulation site for intravenous induction

Participant type(s)

Patient

Age group

Child

Lower age limit

6 Months

Upper age limit

3 Years

Sex

Both

Target number of participants

50

Key exclusion criteria

- 1. Age <6 months or >3 years (>36 months)
- 2. Weight <7 kg or >=17 kg
- 3. Children undergoing urgent or emergency surgical procedures
- 4. Expected duration of surgery <30 minutes
- 5. ASA Grade 3-5
- 6. No written informed consent from parent
- 7. Children with difficult venous access
- 8. Children who need or wish inhalational induction
- 9. Children who will need intermittent positive pressure ventilation along with the use of muscle relaxant
- 10. Patients who need sedative premedication
- 11. Propofol contraindicated (allergy to propofol or its formula components)
- 12. Local anaesthetic cream or gel contraindicated

Date of first enrolment

01/11/2008

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

Scotland

United Kingdom

Study participating centre Department of Anaesthesia

Glasgow United Kingdom G3 8SJ

Sponsor information

Organisation

University of Glasgow (UK)

Sponsor details

c/o Dr Melissa McBride
Research & Development Academic Coordinator
University Avenue
Glasgow
Scotland
United Kingdom
G12 8QQ
melissa.mcbride@ggc.scot.nhs.uk

Sponsor type

University/education

Website

http://www.gla.ac.uk

ROR

https://ror.org/00vtgdb53

Funder(s)

Funder type

Industry

Funder Name

Cardinal Health (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration